A lot of the population through health education on radio and television stations, some health contents on social media, ...

Zydus Lifesciences Limited has launched Semaglutide Injection in India under the brand names SEMAGLYN, MASHEMA, and ALTERME ...

Glenmark Pharmaceuticals Ltd today announced the launch of GLIPIQ® (semaglutide) in India for the management of Type 2 ...

The product was approved by CDSCO after a Phase III clinical study in India that assessed its efficacy and safety in patients ...

Zydus Lifesciences Limited, an innovation-led global lifesciences company, has launched Semaglutide Injection under the brand ...

Glenmark Pharmaceuticals has announced the launch of GLIPIQ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), positioning it as a more affordable GLP-1 therapy aimed at ...

New Delhi, Mar 17 (PTI) Zydus Lifesciences on Tuesday said it has entered into a licensing and supply agreement with Lupin to expand access of diabetes treatment drug Semaglutide Injection (15 mg/3 ml ...

Semaglutide is used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an add-on to the ...

Patients with autoimmune thyroiditis who use semaglutide to manage their T2D have fewer TED-related diagnoses at 5 years.

Following the patent expiry of semaglutide in India, leading pharma companies including Sun Pharma, Dr Reddy’s, Zydus, and ...

Indian pharma majors Sun Pharma, Dr Reddy's and Glenmark on Saturday announced the launch of their generic versions of ...

Glenmark Pharmaceuticals on Saturday announced the launch of GLIPIQⓇ (semaglutide) in India for the management of Type 2 Diabetes Mellitus, aiming to improve affordability and expand access to GLP-1 ...